摘è¦
èƒŒæ™¯ï¼šä»¥å¾€çš„ç ”ç©¶è¡¨æ˜Žï¼Œè‹”è—“æŠ‘ç´ -1,一ç§å¼ºåŠ›çš„PKC调制器和α分泌活化剂,通过长期的(> 10周),腹腔给è¯ï¼ˆi.p.)å¯æ”¹å–„阿尔茨海默æ°ç—…(AD)的认知水平。我们在APPSWE,PSEN1dE985Dbo(APP / PS1)的ADå°é¼ 模型ä¸æ¯”较å¦ä¹ 和空间记忆能力 ï¼Œç ”ç©¶äº†åœ¨æ¤æ¨¡åž‹ä¸æ€¥æ€§è…¹è…”内和å£æœç»™äºˆè‹”è—“æŠ‘ç´ -1对认知缺陷的逆转情况。相比于野生型(WT )å°é¼ ,APP / PS1å°é¼ 表现出显著的å¦ä¹ 能力差,寻找在Morris水迷宫测验ä¸å‘现漂浮æ¿ä½ç½®çš„时间延长。 在进行水迷宫测试å‰è‹”è—“æŠ‘ç´ 1ç»™è¯2å‘¨æ£€æµ‹ç»“æžœï¼šæ€¥æ€§è…¹è…”ç»™äºˆè‹”è—“æŠ‘ç´ 1没有改善延迟,但å£æœç»™äºˆè‹”è—“æŠ‘ç´ 1显著æ高了å°é¼ 记忆能力(通过测é‡ç‰å¾…逃脱时间是å¦å‡å°‘)。在测试的第3å¤©ï¼Œè‹”è—“æŠ‘ç´ -1å£æœç»™è¯çš„æ•ˆæžœæœ€æ˜Žæ˜¾ã€‚è¿™äº›ç ”ç©¶ç»“æžœè¡¨æ˜Žï¼š1)在å¦ä¹ 和记忆模型ä¸ï¼Œè‹”è—“æŠ‘ç´ -1å£æœæœ‰æ•ˆã€‚2)这ç§æ•ˆæžœçš„产生时间å¯ä»¥åœ¨å°‘于2周。3)腹腔注射给è¯æ— 效。我们的结论是å£æœè‹”è—“æŠ‘ç´ 1是未æ¥ä¸´åºŠä¸Šç”¨äºŽæ²»ç–—人类AD的,一ç§æ–°çš„ã€æœ‰æ•ˆã€é•¿æ•ˆçš„记忆增强剂。
关键è¯: β-æ·€ç²‰æ ·è›‹ç™½ï¼Œå»¶ç¼“è¡°è€ï¼Œbryoids,水迷宫,记忆,海马。
Current Alzheimer Research
Title:Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease
Volume: 12 Issue: 1
Author(s): L.M. Schrott, K. Jackson, P. Yi, F. Dietz, G.S. Johnson, T.F. Basting, G. Purdum, T. Tyler, J.D. Rios, T.P. Castor and J.S. Alex
Affiliation:
关键è¯: β-æ·€ç²‰æ ·è›‹ç™½ï¼Œå»¶ç¼“è¡°è€ï¼Œbryoids,水迷宫,记忆,海马。
摘è¦: Background: Previous studies showed that Bryostatin-1, a potent PKC modulator and alphasecretase activator, can improve cognition in models of Alzheimer’s disease (AD) with chronic (>10 weeks), intraperitoneal (i.p.) administration of the drug. We compared learning and spatial memory in the APPswe, PSEN1dE985Dbo (APP/PS1) mouse model of AD and studied the ability of acute intraperitoneal and oral Bryostatin-1 to reverse cognitive deficits in this model. Compared to wild-type (WT) mice, APP/PS1 mice showed significant delays in learning the location of a submerged platform in the Morris water maze. Bryostatin-1 was administered over a 2-week course prior to and during water maze testing. Results: Acute i.p. Bryostatin-1 administration did not improve latency to escape but oral Bryostatin-1 significantly improved memory (measured by a reduction in latency to escape). This benefit of oral Bryostatin-1 administration was most apparent during the first 3 days of testing. These findings show that: 1) Bryostatin-1 is orally active in models of learning and memory, 2) this effect can be produced in less than 2 weeks and 3) this effect is not seen with i.p. administration. We conclude that oral Bryostatin-1 represents a novel, potent and long-acting memory enhancer with future clinical applications in the treatment of human AD.
Export Options
About this article
Cite this article as:
Schrott L.M., Jackson K., Yi P., Dietz F., Johnson G.S., Basting T.F., Purdum G., Tyler T., Rios J.D., Castor T.P. and Alex J.S., Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (1) . https://dx.doi.org/10.2174/1567205012666141218141904
DOI https://dx.doi.org/10.2174/1567205012666141218141904 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Current Pharmaceutical Design Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
Combinatorial Chemistry & High Throughput Screening TNF-α Polymorphisms and Maternal Depression in a Mexican Mestizo Population
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Translational Alzheimer’s Disease Research)
Current Alzheimer Research Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery The Nuclear Transcription Factor CREB: Involvement in Addiction, Deletion Models and Looking Forward
Current Neuropharmacology Crystal Engineering to Design of Solids: From Single to Multicomponent Organic Materials
Mini-Reviews in Organic Chemistry Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression
CNS & Neurological Disorders - Drug Targets Introduction: Strategies, Molecular Targets and Animal Models Useful for Developing Therapies for Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents New Perspectives of Alzheimer Disease Diagnosis – the Most Popular and Future Methods
Medicinal Chemistry The Clinical Potential of Worms and their Products in Treating Inflammatory Diseases
Current Immunology Reviews (Discontinued) High Throughput Screening for Neurodegeneration and Complex Disease Phenotypes
Combinatorial Chemistry & High Throughput Screening The Structural Alteration and Aggregation of Bovine Lens Gamma-Crystallin by Homocysteinylation; The Pathomechanism Underlying Cataract Development During Hyperhomocysteinimia
Protein & Peptide Letters Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anti-Inflammatory and Anti-Apoptotic Effects of Levosimendan in Decompensated Heart Failure: A Novel Mechanism of Drug-Induced Improvement in Contractile Performance of the Failing Heart
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design
Current Neuropharmacology Editorial (Thematic Issue: Natural Products in Cancer Prevention and Therapy, a selection of topics presented in the 2nd Edition PSE Symposium (Naples, Italy, 25th to 28th of June 2013))
Anti-Cancer Agents in Medicinal Chemistry Advanced Glycation End Products in Chinese Medicine Mediated Aging Diseases: A Review
Current Vascular Pharmacology Innate Immune System Modulation During Aging: Contributions of Macrophages and Dendritic Cells
Current Immunology Reviews (Discontinued) Developmental Synaptogenesis and General Anesthesia: A Kiss of Death?
Current Pharmaceutical Design